Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

Immunity

Volumn 39, Issue 1, 2013, Pages 49-60

  Kalos, Michael ^a   June, CarlH ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL SURFACE PROTEIN; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS ANTIGEN; ZINC FINGER NUCLEASE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL EXPANSION; CELL THERAPY; CELL TRANSFORMATION; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CONDITIONING; CYTOKINE RELEASE SYNDROME; ELECTROPORATION; ENGRAFTMENT; EX VIVO STUDY; GAMMA DELTA T LYMPHOCYTE; GENE TRANSFER; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE ACTIVATION SYNDROME; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MUTAGENESIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENESCENCE; SYNTHETIC BIOLOGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; THERAPY; TRANSIENT EXPRESSION; TUMOR IMMUNITY; TUMOR LYSIS SYNDROME; TUMOR MICROENVIRONMENT;

CELL CULTURE TECHNIQUES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SYNTHETIC BIOLOGY; T-LYMPHOCYTES;

EID: 84880733312     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.07.002     Document Type: Review

References (114)

1. Aleksic M., Liddy N., Molloy P.E., Pumphrey N., Vuidepot A., Chang K.M., Jakobsen B.K. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 2012, 42:3174-3179.
2. Au P., Hursh D.A., Lim A., Moos M.C., Oh S.S., Schneider B.S., Witten C.M. FDA oversight of cell therapy clinical trials. Sci. Transl. Med. 2012, 4:49fs31.
3. + Tcells in metastases from melanoma patients. J.Clin. Invest. 2011, 121:2350-2360.
4. Baker M. Companies ponder how truly 'personal' medicines can get. Nat. Med. 2011, 17:519.
5. Behrens E.M., Canna S.W., Slade K., Rao S., Kreiger P.A., Paessler M., Kambayashi T., Koretzky G.A. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J.Clin. Invest. 2011, 121:2264-2277.
6. Bendle G.M., Linnemann C., Hooijkaas A.I., Bies L., de Witte M.A., Jorritsma A., Kaiser A.D.M., Pouw N., Debets R., Kieback E., et al. Lethal graft-versus-host disease in mouse models of Tcell receptor gene therapy. Nat. Med. 2010, 16:565-570. 1p, 570.
7. Berger C., Flowers M.E., Warren E.H., Riddell S.R. Analysis of transgene-specific immune responses that limit the invivo persistence of adoptively transferred HSV-TK-modified donor Tcells after allogeneic hematopoietic cell transplantation. Blood 2006, 107:2294-2302.
8. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ Tcells derived from central memory cells establishes persistent Tcell memory in primates. J.Clin. Invest. 2008, 118:294-305.
9. Berger C., Berger M., Hackman R.C., Gough M., Elliott C., Jensen M.C., Riddell S.R. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009, 114:2417-2426.
10. Bollard C.M., Rössig C., Calonge M.J., Huls M.H., Wagner H.J., Massague J., Brenner M.K., Heslop H.E., Rooney C.M. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99:3179-3187.
11. Brentjens R.J., Rivière I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted Tcells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
12. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M., et al. CD19-targeted Tcells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5:77ra38.
13. Brindley D.A., Davie N.L., Culme-Seymour E.J., Mason C., Smith D.W., Rowley J.A. Peak serum: implications of serum supply for cell therapy manufacturing. Regen. Med. 2012, 7:7-13.
14. Bushman F.D. Retroviral integration and human gene therapy. J.Clin. Invest. 2007, 117:2083-2086.
15. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F., Rosenberg S.A. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 2005, 65:2001-2008.
16. Cheever M.A., Chen W. Therapy with cultured Tcells: principles revisited. Immunol. Rev. 1997, 157:177-194.
17. Chen Y.Y., Galloway K.E., Smolke C.D. Synthetic biology: advancing biological frontiers by building synthetic systems. Genome Biol. 2012, 13:240.
18. Cheng L.E., Ohlén C., Nelson B.H., Greenberg P.D. Enhanced signaling through the IL-2 receptor in CD8+ Tcells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ Tcells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA 2002, 99:3001-3006.
19. Chervin A.S., Aggen D.H., Raseman J.M., Kranz D.M. Engineering higher affinity Tcell receptors using a Tcell display system. J.Immunol. Methods 2008, 339:175-184.
20. Cole D.K., Pumphrey N.J., Boulter J.M., Sami M., Bell J.I., Gostick E., Price D.A., Gao G.F., Sewell A.K., Jakobsen B.K. Human TCR-binding affinity is governed by MHC class restriction. J.Immunol. 2007, 178:5727-5734.
21. Dao T., Yan S., Veomett N., Pankov D., Zhou L., Korontsvit T., Scott A., Whitten J., Maslak P., Casey E., et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci. Transl. Med. 2013, 5:76ra33.
22. Davis J.L., Theoret M.R., Zheng Z., Lamers C.H., Rosenberg S.A., Morgan R.A. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 2010, 16:5852-5861.
23. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., Straathof K., Liu E., Durett A.G., Grilley B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N.Engl. J. Med. 2011, 365:1673-1683.
24. Dotti G., Savoldo B., Pule M., Straathof K.C., Biagi E., Yvon E., Vigouroux S., Brenner M.K., Rooney C.M. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005, 105:4677-4684.
25. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
26. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J.Clin. Oncol. 2008, 26:5233-5239.
27. Eaton D., Gilham D.E., O'Neill A., Hawkins R.E. Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes invitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. 2002, 9:527-535.
28. Evans L.S., Witte P.R., Feldhaus A.L., Nelson B.H., Riddell S.R., Greenberg P.D., Lupton S.D., Jones L.A. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Hum. Gene Ther. 1999, 10:1941-1951.
29. Fisher D.T., Chen Q., Appenheimer M.M., Skitzki J., Wang W.C., Odunsi K., Evans S.S. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol. Invest. 2006, 35:251-277.
30. Fisher D.T., Chen Q., Skitzki J.J., Muhitch J.B., Zhou L., Appenheimer M.M., Vardam T.D., Weis E.L., Passanese J., Wang W.C., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic Tcells. J.Clin. Invest. 2011, 121:3846-3859.
31. Friedland A.E., Lu T.K., Wang X., Shi D., Church G., Collins J.J. Synthetic gene networks that count. Science 2009, 324:1199-1202.
32. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., Gostick E., Yu Z., Carpenito C., et al. A human memory Tcell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
33. Greenberg P.D. Adoptive Tcell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 1991, 49:281-355.
34. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 1989, 86:10024-10028.
35. Grupp S.A., Prak E.L., Boyer J., McDonald K.R., Shusterman S., Thompson E., Callahan C., Jawad A.F., Levine B.L., June C.H., Sullivan K.E. Adoptive transfer of autologous Tcells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin. Cancer Res. 2012, 18:6732-6741.
36. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified Tcells for acute lymphoid leukemia. N.Engl. J. Med. 2013, 368:1509-1518.
37. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J.Clin. Invest. 2008, 118:3132-3142.
38. Hackett P.B., Largaespada D.A., Cooper L.J. A transposon and transposase system for human application. Mol. Ther. 2010, 18:674-683.
39. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
40. Hinrichs C.S., Borman Z.A., Cassard L., Gattinoni L., Spolski R., Yu Z., Sanchez-Perez L., Muranski P., Kern S.J., Logun C., et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ Tcells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 2009, 106:17469-17474.
41. Hsu C., Jones S.A., Cohen C.J., Zheng Z., Kerstann K., Zhou J., Robbins P.F., Peng P.D., Shen X., Gomes T.J., et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007, 109:5168-5177.
42. Jensen M.C., Popplewell L., Cooper L.J., DiGiusto D., Kalos M., Ostberg J.R., Forman S.J. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected Tcells in humans. Biol. Blood Marrow Transplant. 2010, 16:1245-1256.
43. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
44. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 2009, 9:704-716.
45. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
46. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J.Clin. Invest. 2011, 121:4746-4757.
47. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., et al. A phase I study on adoptive immunotherapy using gene-modified Tcells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
48. Kircher M.F., Allport J.R., Graves E.E., Love V., Josephson L., Lichtman A.H., Weissleder R. Invivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003, 63:6838-6846.
49. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances Tcell-mediated tumor immunotherapy. Trends Immunol. 2005, 26:111-117.
50. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced Tcells. Blood 2012, 119:2709-2720.
51. Krause A., Guo H.F., Latouche J.B., Tan C., Cheung N.K., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J.Exp. Med. 1998, 188:619-626.
52. Ku C.C., Murakami M., Sakamoto A., Kappler J., Marrack P. Control of homeostasis of CD8+ memory Tcells by opposing cytokines. Science 2000, 288:675-678.
53. Kuball J., Hauptrock B., Malina V., Antunes E., Voss R.H., Wolfl M., Strong R., Theobald M., Greenberg P.D. Increasing functional avidity of TCR-redirected Tcells by removing defined N-glycosylation sites in the TCR constant domain. J.Exp. Med. 2009, 206:463-475.
54. Lamers C.H., Willemsen R., van Elzakker P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., Oosterwijk E., Sleijfer S., Debets R., Gratama J.W. Immune responses to transgene and retroviral vector in patients treated with exvivo-engineered Tcells. Blood 2011, 117:72-82.
55. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered Tcells: clinical evaluation and management of on-target toxicity. Mol. Ther. 2013, 21:904-912.
56. Laport G.G., Levine B.L., Stadtmauer E.A., Schuster S.J., Luger S.M., Grupp S., Bunin N., Strobl F.J., Cotte J., Zheng Z., et al. Adoptive transfer of costimulated Tcells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003, 102:2004-2013.
57. Li Y., Moysey R., Molloy P.E., Vuidepot A.L., Mahon T., Baston E., Dunn S., Liddy N., Jacob J., Jakobsen B.K., Boulter J.M. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 2005, 23:349-354.
58. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced Tcells in myeloma and melanoma. Blood 2013, Published online June 14, 2013. 10.1182/blood-2013-03-490565.
59. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 2006, 24:657-679.
60. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., Okoye F.I., Jaffee E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61:3689-3697.
61. MacKie R.M., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N.Engl. J. Med. 2003, 348:567-568.
62. Macy E., Bulpitt K., Champlin R.E., Saxon A. Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin. J. Allergy Clin. Immunol. 1989, 83:871-875.
63. Marktel S., Magnani Z., Ciceri F., Cazzaniga S., Riddell S.R., Traversari C., Bordignon C., Bonini C. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003, 101:1290-1298.
64. Mason C., Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 2010, 5:307-313.
65. Maus M.V., Haas A.R., Beatty G.L., Albelda S.M., Levine B.L., Liu X., Zhao Y., Kalos M., June C.H. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer. Immunol. Res. 2013, Published online April 7, 2013. 10.1158/2326-6066.CIR-13-0006.
66. Michalos G., Makris S., Papakostas N., Mourtzis D., Chryssolouris G. Automotive assembly technologies review: challenges and outlook for a flexible and adaptive approach. CIRO J. Manuf. Sci. Technol. 2010, 2:81-91.
67. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
68. Mitchell D.A., Karikari I., Cui X., Xie W., Schmittling R., Sampson J.H. Selective modification of antigen-specific Tcells by RNA electroporation. Hum. Gene Ther. 2008, 19:511-521.
69. Mitchison N.A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J.Exp. Med. 1955, 102:157-177.
70. Mitsuyasu R.T., Anton P.A., Deeks S.G., Scadden D.T., Connick E., Downs M.T., Bakker A., Roberts M.R., June C.H., Jalali S., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) Tcells in human immunodeficiency virus-infected subjects. Blood 2000, 96:785-793.
71. Moon E.K., Carpenito C., Sun J., Wang L.C., Kapoor V., Predina J., Powell D.J., Riley J.L., June C.H., Albelda S.M. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human Tcells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 2011, 17:4719-4730.
72. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of Tcells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
73. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J.Immunother. 2013, 36:133-151.
74. Muranski P., Boni A., Wrzesinski C., Citrin D.E., Rosenberg S.A., Childs R., Restifo N.P. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat. Clin. Pract. Oncol. 2006, 3:668-681.
75. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
76. Muul L.M., Tuschong L.M., Soenen S.L., Jagadeesh G.J., Ramsey W.J., Long Z., Carter C.S., Garabedian E.K., Alleyne M., Brown M., et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003, 101:2563-2569.
77. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. Invivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
78. Nolz J.C., Starbeck-Miller G.R., Harty J.T. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 2011, 3:1223-1233.
79. O'Connor C.M., Sheppard S., Hartline C.A., Huls H., Johnson M., Palla S.L., Maiti S., Ma W., Davis R.E., Craig S., et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci. Rep. 2012, 2:249.
80. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
81. Olson J.A., McDonald-Hyman C., Jameson S.C., Hamilton S.E. Effector-like CD8(+) Tcells in the memory population mediate potent protective immunity. Immunity 2013, 38:1250-1260.
82. Park J.R., Digiusto D.L., Slovak M., Wright C., Naranjo A., Wagner J., Meechoovet H.B., Bautista C., Chang W.C., Ostberg J.R., Jensen M.C. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 2007, 15:825-833.
83. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
84. Paulos C.M., Carpenito C., Plesa G., Suhoski M.M., Varela-Rohena A., Golovina T.N., Carroll R.G., Riley J.L., June C.H. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci. Transl. Med. 2010, 2:55ra78.
85. Peggs K.S., Thomson K., Hart D.P., Geary J., Morris E.C., Yong K., Goldstone A.H., Linch D.C., Mackinnon S. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
86. Pegram H.J., Lee J.C., Hayman E.G., Imperato G.H., Tedder T.F., Sadelain M., Brentjens R.J. Tumor-targeted Tcells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119:4133-4141.
87. Perez E.E., Wang J., Miller J.C., Jouvenot Y., Kim K.A., Liu O., Wang N., Lee G., Bartsevich V.V., Lee Y.L., et al. Establishment of HIV-1 resistance in CD4+ Tcells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26:808-816.
88. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified Tcells in chronic lymphoid leukemia. N.Engl. J. Med. 2011, 365:725-733.
89. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z., et al. Virus-specific Tcells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14:1264-1270.
90. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., Blasberg R., Yagita H., Muranski P., Antony P.A., et al. Tumor-reactive CD4(+) Tcells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J.Exp. Med. 2010, 207:637-650.
91. Rapoport A.P., Stadtmauer E.A., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E.A., Zheng Z., Westphal S., Mair R., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 2005, 11:1230-1237.
92. Rapoport A.P., Stadtmauer E.A., Aqui N., Vogl D., Chew A., Fang H.B., Janofsky S., Yager K., Veloso E., Zheng Z., et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous Tcells. Clin. Cancer Res. 2009, 15:4499-4507.
93. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the Tcell response. Nat. Rev. Immunol. 2012, 12:269-281.
94. Reyon D., Tsai S.Q., Khayter C., Foden J.A., Sander J.D., Joung J.K. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 2012, 30:460-465.
95. Rowley J., Monie A., Hung C.F., Wu T.C. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ Tcells modifies adoptively transferred T-cell function in cis. Eur. J. Immunol. 2009, 39:491-506.
96. Rufer N., Migliaccio M., Antonchuk J., Humphries R.K., Roosnek E., Lansdorp P.M. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001, 98:597-603.
97. Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013, 3:388-398.
98. Scholler J., Brady T.L., Binder-Scholl G., Hwang W.-T., Plesa G., Hege K.M., Vogel A.N., Kalos M., Riley J.L., Deeks S.G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor Tcells. Sci. Transl. Med. 2012, 4:32ra53.
99. Stemberger C., Huster K.M., Koffler M., Anderl F., Schiemann M., Wagner H., Busch D.H. A single naive CD8+ Tcell precursor can develop into diverse effector and memory subsets. Immunity 2007, 27:985-997.
100. Sun J.C., Bevan M.J. Defective CD8 Tcell memory following acute infection without CD4 Tcell help. Science 2003, 300:339-342.
101. Sun J.C., Williams M.A., Bevan M.J. CD4+ Tcells are required for the maintenance, not programming, of memory CD8+ Tcells after acute infection. Nat. Immunol. 2004, 5:927-933.
102. Tang Y., Xu X., Song H., Yang S., Shi S., Wei J., Pan B., Zhao F., Liao C., Luo C. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br. J. Haematol. 2008, 143:84-91.
103. Topp M.S., Riddell S.R., Akatsuka Y., Jensen M.C., Blattman J.N., Greenberg P.D. Restoration of CD28 expression in CD28- CD8+ memory effector Tcells reconstitutes antigen-induced IL-2 production. J.Exp. Med. 2003, 198:947-955.
104. Turtle C.J., Riddell S.R. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr. Opin. Immunol. 2011, 23:299-305.
105. Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., Donato F., Wang X., Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 2005, 11:67-72.
106. Wang G.P., Levine B.L., Binder G.K., Berry C.C., Malani N., McGarrity G., Tebas P., June C.H., Bushman F.D. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ Tcells. Mol. Ther. 2009, 17:844-850.
107. Wang X., Naranjo A., Brown C.E., Bautista C., Wong C.W., Chang W.C., Aguilar B., Ostberg J.R., Riddell S.R., Forman S.J., Jensen M.C. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory Tcells manufactured at clinical scale. J.Immunother. 2012, 35:689-701.
108. Williams D.A. Foamy virus vectors come of age. Mol. Ther. 2008, 16:635-636.
109. Wrzesinski C., Restifo N.P. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 2005, 17:195-201.
110. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive Tcell therapy using antigen-specific CD8+ Tcell clones for the treatment of patients with metastatic melanoma: invivo persistence, migration, and antitumor effect of transferred Tcells. Proc. Natl. Acad. Sci. USA 2002, 99:16168-16173.
111. Yoon S.H., Lee J.M., Cho H.I., Kim E.K., Kim H.S., Park M.Y., Kim T.G. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2009, 16:489-497.
112. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., Long L.M., Bernstein D., Hill B.J., Douek D.C., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory Tcells. Nat. Med. 2005, 11:1238-1243.
113. Zhao Y., Bennett A.D., Zheng Z., Wang Q.J., Robbins P.F., Yu L.Y., Li Y., Molloy P.E., Dunn S.M., Jakobsen B.K., et al. High-affinity TCRs generated by phage display provide CD4+ Tcells with the ability to recognize and kill tumor cell lines. J.Immunol. 2007, 179:5845-5854.
114. Zhao Y., Moon E., Carpenito C., Paulos C.M., Liu X., Brennan A., Chew A., Carroll R.G., Scholler J., Levine B.L., et al. Multiple injections of electroporated autologous Tcells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010, 70:9053-9061.